Ione O C Woollacott1, Jennifer M Nicholas2, Carolin Heller3, Martha S Foiani3, Katrina M Moore1, Lucy L Russell1, Ross W Paterson1, Ashvini Keshavan1, Jonathan M Schott1, Jason D Warren1, Amanda Heslegrave3, Henrik Zetterberg3,4,5, Jonathan D Rohrer6. 1. Dementia Research Centre, Department of Neurodegenerative Disease, Queen Square UCL Institute of Neurology, London, United Kingdom. 2. Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom. 3. UK Dementia Research Institute, Department of Neurodegenerative Disease, Queen Square UCL Institute of Neurology, London, United Kingdom. 4. Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden. 5. Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden. 6. Dementia Research Centre, Department of Neurodegenerative Disease, Queen Square UCL Institute of Neurology, London, United Kingdom, j.rohrer@ucl.ac.uk.
Abstract
BACKGROUND: Chronic glial dysfunction may contribute to the pathogenesis of frontotemporal dementia (FTD). Cerebrospinal fluid (CSF) levels of glia-derived proteins YKL-40 and chitotriosidase are increased in Alzheimer's disease (AD) but have not been explored in detail across the spectrum of FTD. METHODS: We investigated whether CSF YKL-40 and chitotriosidase levels differed between FTD patients and controls, across different clinical and genetic subtypes of FTD, and between individuals with a clinical FTD syndrome due to AD versus non-AD (frontotemporal lobar degeneration, FTLD) pathology (based on CSF neurodegenerative biomarkers). Eighteen healthy controls and 64 people with FTD (behavioural variant FTD, n = 20; primary progressive aphasia [PPA], n = 44: nfvPPA, n = 16, svPPA, n = 11, lvPPA, n = 14, PPA-NOS, n = 3) were included. 10/64 had familial FTD, with mutations in GRN(n = 3), MAPT(n = 4), or C9orf72 (n = 3). 15/64 had neurodegenerative biomarkers consistent with AD pathology. Levels were measured by immunoassay and compared using multiple linear regressions. We also examined relationships of YKL-40 and chitotriosidase with CSF total tau (T-tau), phosphorylated tau 181 (P-tau) and β-amyloid 1-42 (Aβ42), with each other, and with age and disease du-ration. RESULTS: CSF YKL-40 and chitotriosidase levels were higher in FTD, particularly lvPPA (both) and nfvPPA (YKL-40), compared with controls. GRN mutation carriers had higher levels of both proteins than controls and C9orf72 expansion carriers, and YKL-40 was higher in MAPT mutation carriers than controls. Individuals with underlying AD pathology had higher YKL-40 and chitotriosidase levels than both controls and those with likely FTLD pathology. CSF YKL-40 and chitotriosidase levels were variably associated with levels of T-tau, P-tau and Aβ42, and with each other, depending on clinical syndrome and underlying pathology. CSF YKL-40 but not chitotriosidase was associated with age, but not disease duration. CONCLUSION: CSF YKL-40 and chitotriosidase levels are increased in individuals with clinical FTD syndromes, particularly due to AD pathology. In a preliminary analysis of genetic groups, levels of both proteins are found to be highly elevated in FTD due to GRN mutations, while YKL-40 is increased in individuals with MAPT mutations. As glia-derived protein levels generally correlate with T-tau and P-tau levels, they may reflect the glial response to neurodegeneration in FTLD.
BACKGROUND:Chronic glial dysfunction may contribute to the pathogenesis of frontotemporal dementia (FTD). Cerebrospinal fluid (CSF) levels of glia-derived proteins YKL-40 and chitotriosidase are increased in Alzheimer's disease (AD) but have not been explored in detail across the spectrum of FTD. METHODS: We investigated whether CSF YKL-40 and chitotriosidase levels differed between FTDpatients and controls, across different clinical and genetic subtypes of FTD, and between individuals with a clinical FTD syndrome due to AD versus non-AD (frontotemporal lobar degeneration, FTLD) pathology (based on CSF neurodegenerative biomarkers). Eighteen healthy controls and 64 people with FTD (behavioural variant FTD, n = 20; primary progressive aphasia [PPA], n = 44: nfvPPA, n = 16, svPPA, n = 11, lvPPA, n = 14, PPA-NOS, n = 3) were included. 10/64 had familial FTD, with mutations in GRN(n = 3), MAPT(n = 4), or C9orf72 (n = 3). 15/64 had neurodegenerative biomarkers consistent with AD pathology. Levels were measured by immunoassay and compared using multiple linear regressions. We also examined relationships of YKL-40 and chitotriosidase with CSF total tau (T-tau), phosphorylated tau 181 (P-tau) and β-amyloid 1-42 (Aβ42), with each other, and with age and disease du-ration. RESULTS: CSF YKL-40 and chitotriosidase levels were higher in FTD, particularly lvPPA (both) and nfvPPA (YKL-40), compared with controls. GRN mutation carriers had higher levels of both proteins than controls and C9orf72 expansion carriers, and YKL-40 was higher in MAPT mutation carriers than controls. Individuals with underlying AD pathology had higher YKL-40 and chitotriosidase levels than both controls and those with likely FTLD pathology. CSF YKL-40 and chitotriosidase levels were variably associated with levels of T-tau, P-tau and Aβ42, and with each other, depending on clinical syndrome and underlying pathology. CSF YKL-40 but not chitotriosidase was associated with age, but not disease duration. CONCLUSION: CSF YKL-40 and chitotriosidase levels are increased in individuals with clinical FTD syndromes, particularly due to AD pathology. In a preliminary analysis of genetic groups, levels of both proteins are found to be highly elevated in FTD due to GRN mutations, while YKL-40 is increased in individuals with MAPT mutations. As glia-derived protein levels generally correlate with T-tau and P-tau levels, they may reflect the glial response to neurodegeneration in FTLD.
Authors: Zachary A Miller; Katherine P Rankin; Neill R Graff-Radford; Leonel T Takada; Virginia E Sturm; Clare M Cleveland; Lindsey A Criswell; Philipp A Jaeger; Trisha Stan; Kristin A Heggeli; Sandy Chan Hsu; Anna Karydas; Baber K Khan; Lea T Grinberg; Maria Luisa Gorno-Tempini; Adam L Boxer; Howard J Rosen; Joel H Kramer; Giovanni Coppola; Daniel H Geschwind; Rosa Rademakers; William W Seeley; Tony Wyss-Coray; Bruce L Miller Journal: J Neurol Neurosurg Psychiatry Date: 2013-03-30 Impact factor: 10.154
Authors: D T Ohm; G Kim; T Gefen; A Rademaker; S Weintraub; E H Bigio; M-M Mesulam; E Rogalski; C Geula Journal: Neuropathol Appl Neurobiol Date: 2018-05-17 Impact factor: 8.090
Authors: Hansen Lui; Jiasheng Zhang; Stefanie R Makinson; Michelle K Cahill; Kevin W Kelley; Hsin-Yi Huang; Yulei Shang; Michael C Oldham; Lauren Herl Martens; Fuying Gao; Giovanni Coppola; Steven A Sloan; Christine L Hsieh; Charles C Kim; Eileen H Bigio; Sandra Weintraub; Marek-Marsel Mesulam; Rosa Rademakers; Ian R Mackenzie; William W Seeley; Anna Karydas; Bruce L Miller; Barbara Borroni; Roberta Ghidoni; Robert V Farese; Jeanne T Paz; Ben A Barres; Eric J Huang Journal: Cell Date: 2016-04-21 Impact factor: 41.582
Authors: Daniel Alcolea; María Carmona-Iragui; Marc Suárez-Calvet; M Belén Sánchez-Saudinós; Isabel Sala; Sofía Antón-Aguirre; Rafael Blesa; Jordi Clarimón; Juan Fortea; Alberto Lleó Journal: J Alzheimers Dis Date: 2014 Impact factor: 4.472
Authors: Kelsey E Melah; Sharon Yuan-Fu Lu; Siobhan M Hoscheidt; Andrew L Alexander; Nagesh Adluru; Daniel J Destiche; Cynthia M Carlsson; Henrik Zetterberg; Kaj Blennow; Ozioma C Okonkwo; Carey E Gleason; N Maritza Dowling; Lisa C Bratzke; Howard A Rowley; Mark A Sager; Sanjay Asthana; Sterling C Johnson; Barbara B Bendlin Journal: J Alzheimers Dis Date: 2016 Impact factor: 4.472
Authors: Charlotte E Teunissen; Naura Elias; Marleen J A Koel-Simmelink; Sisi Durieux-Lu; Arjan Malekzadeh; Thang V Pham; Sander R Piersma; Tommaso Beccari; Lieke H H Meeter; Elise G P Dopper; John C van Swieten; Connie R Jimenez; Yolande A L Pijnenburg Journal: Alzheimers Dement (Amst) Date: 2016-01-19
Authors: Ione O C Woollacott; Martina Bocchetta; Carole H Sudre; Basil H Ridha; Catherine Strand; Robert Courtney; Sebastien Ourselin; M Jorge Cardoso; Jason D Warren; Martin N Rossor; Tamas Revesz; Nick C Fox; Janice L Holton; Tammaryn Lashley; Jonathan D Rohrer Journal: Neurocase Date: 2018-08-16 Impact factor: 0.881
Authors: Kevin Connolly; Mikael Lehoux; Ryan O'Rourke; Benedetta Assetta; Guzide Ayse Erdemir; Jack A Elias; Chun Geun Lee; Yu-Wen Alvin Huang Journal: Alzheimers Dement Date: 2022-03-02 Impact factor: 16.655
Authors: Jared S Katzeff; Fiona Bright; Katherine Phan; Jillian J Kril; Lars M Ittner; Michael Kassiou; John R Hodges; Olivier Piguet; Matthew C Kiernan; Glenda M Halliday; Woojin Scott Kim Journal: Brain Date: 2022-06-03 Impact factor: 15.255
Authors: Yanaika S Hok-A-Hin; Jeroen J M Hoozemans; William T Hu; Dorine Wouters; Jennifer C Howell; Alberto Rábano; Wiesje M van der Flier; Yolande A L Pijnenburg; Charlotte E Teunissen; Marta Del Campo Journal: Alzheimers Res Ther Date: 2022-07-25 Impact factor: 8.823
Authors: Emma L van der Ende; Carolin Heller; Jonathan D Rohrer; Harro Seelaar; Aitana Sogorb-Esteve; Imogen J Swift; David McFall; Georgia Peakman; Arabella Bouzigues; Jackie M Poos; Lize C Jiskoot; Jessica L Panman; Janne M Papma; Lieke H Meeter; Elise G P Dopper; Martina Bocchetta; Emily Todd; David Cash; Caroline Graff; Matthis Synofzik; Fermin Moreno; Elizabeth Finger; Raquel Sanchez-Valle; Rik Vandenberghe; Robert Laforce; Mario Masellis; Maria Carmela Tartaglia; James B Rowe; Chris Butler; Simon Ducharme; Alexander Gerhard; Adrian Danek; Johannes Levin; Yolande A L Pijnenburg; Markus Otto; Barbara Borroni; Fabrizio Tagliavini; Alexandre de Mendonça; Isabel Santana; Daniela Galimberti; Sandro Sorbi; Henrik Zetterberg; Eric Huang; John C van Swieten Journal: J Neuroinflammation Date: 2022-09-05 Impact factor: 9.587